Survival difference among patients with hepatocelluar carcinoma (HCC) based on stage of disease: The pre- and post-sorafenib era.

2017 ◽  
Vol 35 (4_suppl) ◽  
pp. 411-411
Author(s):  
Chintan Shah ◽  
Hardik Satish Chhatrala ◽  
Kinjal Vora ◽  
Rohit Bishnoi ◽  
Harini Bejjanki ◽  
...  
Keyword(s):  
Vascular Invasion ◽  
Survival Rates ◽  
Relative Survival ◽  
P Value ◽  
Advanced Stage ◽  
Seer Database ◽  
Multiple Tumors ◽  
Survival Difference ◽  
Significant Difference ◽  
Solitary Tumor

411 Background: Sorafenib was approved for unresectable and metastatic HCC in 2007. We conducted this retrospective study using U.S. Surveillance, Epidemiology and End results (SEER) database to evaluate the relative survival rates of HCC patients before and after the approval of sorafenib. Methods: We analyzed SEER database: Incidence - SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2015 Sub (1973-2013 varying). Relative survival at 12,24,36,48 and 60 months interval was measured for patients diagnosed with HCC between 2001 and 2013. Relative survival rates were compared between pre sorafenib (2001-2007) and post sorafenib (2008-2013) eras. Results: A total of 54,901 patients (23,963 in pre sorafenib era and 30,938 in post-sorafenib era) were reported with HCC in SEER database. Relative survival at 5-years significantly improved for HCC patients diagnosed after 2007 (16.00±0.30% vs 18.90±0.30% for pre and post sorafenib era respectively; P-value < 0.001). Relative survival for HCC patients with the solitary tumor was significantly improved (33.10±0.80% vs 35.40±0.90% survival at 5 years for pre and post sorafenib era respectively; P-value < 0.001). Similarly, survival was found to be significantly improved for patients with multiple tumors without vascular invasion (17.10±0.70% vs 19.40±0.80% survival at 5 years for pre and post sorafenib era respectively; p-value < 0.001). Relative survival continued to be poor with no statistically significant difference at any intervals for patients with tumor with vascular invasion (P-value 0.748) or distant metastasis (P-value 0.055). Survival difference was not significant among different age groups and gender between pre and post sorafenib eras. Conclusions: While relative survival significantly improved in post sorafenib era, it is largely limited to patients with the localized disease with the solitary tumor or multiple tumors without any vascular invasion or metastasis. Survival in patients with advanced stage HCC remains poor and has not shown significant improvement since the approval of sorafenib. The study shows better alternatives are needed for advanced-stage unresectable HCC patients.

Survival trends among patients with advanced hepatocellular carcinoma in the United States.

2013 ◽  
Vol 31 (4_suppl) ◽  
pp. 329-329
Author(s):  
Krishna Bilas Ghimire ◽  
Binay Kumar Shah ◽  
Barsha Nepal
Keyword(s):  
Survival Rates ◽  
Age Groups ◽  
Stage Iv ◽  
Relative Survival ◽  
The United States ◽  
P Value ◽  
Advanced Hepatocellular Carcinoma ◽  
Z Score ◽  
Significant Difference ◽  
End Results

329 Background: Sorafenib was approved by FDA for treatment of HCC in 2007. This study was conducted to evaluate survival outcome in advanced HCC during 2005-2006 and 2008-2009 using U.S. Surveillance, Epidemiology, and End Results (SEER) cancer registry database.Methods: We analyzed the Surveillance, Epidemiology, and End Results (SEER*Stat) database: Incidence - SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2011 Sub (1973-2009 varying) using MP-SIR session. We analysed 1 year relative survival rates among stage IV HCC patients between pre- sorafenib (2005- 2006) and post- sorafenib (2008- 2009) eras. We used seer Z test to compare relative survival rates among cohorts of patients categorized by gender and age groups (<50 and >50 years). Results: There were 2,497 (1,180 in pre-sorafenib era and 1,317 in post-sorafenib era) stage IV HCC patients reported in seer database. Overall 1 year relative survival rates ± standard error (SE) were: 12.5±0.7% (12.5±1% in pre sorafenib era vs 13.1±1.1% in post sorafenib era, Z score= 0.481, p value=0.63). Overall Relative survival rates among men and women were 12.9±0.8% (12.7±1.1% in pre vs 13.4±1.2 in post sorafenib era, Z score=0.254, p value=0.79) and 11.8±1.6% (11.7±2.2% in pre vs 11.5±2.5 post sorafenib era, Z score=0.469, p value=0.63) respectively. There was no significant differences between 1 year relative survival rates by age groups (<50 and >50 years). Conclusions: This study showed no significant difference in 1-year relative survival rates during 2008-2009 as compared to 2005-2006. More studies are required to find out why the findings of SHARP trial have not translated to population-based settings.[Table: see text]

Survival of elderly patients with advanced hepatocellular carcinoma with distant metastasis in pre- and post- sorafenib era: A population based study.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e15643-e15643 ◽  
Author(s):  
Nibash Budhathoki ◽  
Binay Kumar Shah
Keyword(s):  
Hepatocellular Carcinoma ◽  
Elderly Patients ◽  
Distant Metastasis ◽  
Survival Rates ◽  
Relative Survival ◽  
Population Based ◽  
P Value ◽  
Advanced Hepatocellular Carcinoma ◽  
Significant Difference ◽  
Improvement In Survival

e15643 Background: Sorafinib was approved for advanced hepatocellular carcinoma in 2007. This study was conducted to study relative survival in elderly patients with advanced hepatocellular carcinoma in presorafinib and sorafinib era. Methods: We selected elderly patients (age ≥ 65 years) with advanced hepatocellular carcinoma (distant metastasis based on SEER’s LRD staging) from the Surveillance, Epidemiology, and End Results (SEER) database diagnosed during January 2000 to December 2013. We calculated one year and five year relative survival rates in pre- (2000-2006) and post- sorafinib (2008-2013) era by sex and ethnicity (Caucasians, African-Americans (AA) & Other) using SEER*Stat software. Results: There were total of 1533 patients in presorafinib era and 1694 patients in postsorafinib era. Of the total population, 71.30% were male and 28.70% female, 71% were Caucasian, 10% African-American and 19% were other race. Median age of patients was 73 years (65-99 years) and medial follow up period was 3 months (0-167 months) Survival rates improved significantly from pre- to post- sorafenib era (1 year RS: 10.60% ±0.80% vs 12.10±0.90%, p value = 0.001; 5 year RS: 1.10%±0.30% vs 1.8%±0.6%, p value = 0.001 ). The survival rate improved significantly for male (1 year RS: 11.60%±1.00% vs 12.30%±1.00%, p value = 0.006; 5 year RS: 1.00%±0.40% vs 1.3%± 0.6% , p value = 0.007) and Caucasian (1 year RS: 10.60%±1.00% vs 12.60%±1.10%, p value = 0.0008; 5 year RS: RS = 1.20%±0.40% vs 1.4%±0.7%, P value = 0.001) patients in post sorafenib era. There was no significant difference in the survival rates among any other cohorts examined.However in black (N = 153 vs 158 , RS = 6.80%±2.10% vs 7.80%±2.40% , p value = 0.77) or other races (N = 311 vs 311, RS = 12.20%±1.90% vs 12.80%±2.10%, p value = 0.30 ) , no significant improvement in survival was noted. Conclusions: Our study showed that relative survival rates of elderly patients with advanced hepatocellular carcinoma with distant metastasis has improved in the post-sorafenib compared to pre-sorafenib era. The improvement in survival is limited to male and Caucasian patients.

Appendiceal adenocarcinoma: Analysis of SEER database.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e18097-e18097
Author(s):  
Sreenivasa Rao Chandana ◽  
Chintan Shah
Keyword(s):  
Hurricane Katrina ◽  
Incidence Rate ◽  
Survival Rates ◽  
Relative Survival ◽  
Signet Ring Cell ◽  
Seer Database ◽  
Poor Survival ◽  
Appendiceal Adenocarcinoma ◽  
Survival Difference ◽  
Before And After

e18097 Background: Appediceal cancers (AC) are rare, and often found on appendectomies. Adenocarcinomas represents approximately two-thirds of all AC. We performed the analysis of SEER database to understand the overall incidence and survival trends. Methods: We analyzed SEER database: Incidence - SEER 18 RegsResearch Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2015 Sub (1973-2013 varying). Cases diagnosed of AC between 1988 and 2013 were identified. Trend of incidence rate was calculated. Relative survival rates (RSR) were calculated stratified by age, gender, race, stage, histological subtypes which were divided into mucinous, non-mucinous and signet ring cell carcinoma (SRCC). We calculated survival difference for patient diagnosed before and after 2000. Results: Age adjusted incidence rate of appendiceal adenocarcinoma was 0.4 cases per 100,000 person years. Overall incidence rate increased on average 3.7% per 100,000 person years (P < 0.05). The highest increase was seen in SRCC (4.8% per 100,000 person years). Survival was worst in SRCC (5 years RSR-28.40%) compared to other types (5 year RSR- 61.0% and 52.90% for mucinous and non-mucinous carcinoma (P < 0.01). Survival significantly improved for patients diagnosed after 2000 for mucinous (5 years RSR -51.90% and 64.30%) and SRCC (5 year RSR-18.0% and 31.0%), respectively before and after 2000 in each category. No improvement in survival was found in non-mucinous carcinomas since 2000. While survival among different histological types was not different for localized disease, it was significantly better for regional or distant stages in mucinous cancers when compared to non-mucinous cancers (P < 0.01). Elderly patient ( > 65 years) showed significantly poor survival for mucinous and non-mucinous carcinomas, while there was no variation in survival based on age for SRCC. Moreover, females showed significantly poor survival (P < 0.05) compared to males for SRCC, while no variation in survival based on gender for other types. Survival was not different among different races. Conclusions: Incidence of appendiceal adenocarcinomas is increasing. The highest increase is seen in SRCC which has the worst survival. Survival from mucinous adenocarcinomas has improved significantly in last decade.

Survival rates of male breast cancer compared to female: A Surveillance, Epidemiology, and End Results (SEER) database analysis.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 6567-6567
Author(s):  
Rao Mushtaq ◽  
Mohammed Shaik ◽  
Shams Mistry ◽  
Omar Abed Alkharabsheh ◽  
Mahmoud Shaqfeh ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Male Breast Cancer ◽  
Black Males ◽  
Survival Rates ◽  
Male Breast ◽  
Seer Database ◽  
Black Females ◽  
Kaplan Meier ◽  
Survival Difference ◽  
Significant Difference

6567 Background: Breast cancer (BC) is rare in males (M) compared to females (F). There were 2,190 new cases of MBC out of total 226,870 BC cases diagnosed in 2012. Recently, the incidence of MBC is rising but mortality is decreasing in both MBC and FBC. Therefore we want to evaluate survival difference between MBC and FBC. Methods: Using SEER database we analyzed 4,192 MBC compared to 591,268 FBC diagnosed between 1983-2009. Data including age, sex, tumor size, grade, stage, and ER/PR status was used in analysis. Overall five year survival (OS) and Disease specific survival (DSS) rates were calculated using Kaplan-Meier (KM). We further analyzed the data based on race (Black vs White) and calculated 5yr-OS and 5yr-DSS using KM. Results: The majority of MBC were diagnosed at later stages (49.2% vs 35.3%), with greater number of +veLN (44% vs33.5%), and higher percentage of positive ER/PR(95% vs79%) compared to FBC. When analyzed stage-by-stage, males had significantly lower 5-yrOS in all stages except in the stage with distant metastasis (mets) (Table1a). There was no significant difference in 5-yr DSS survival in both sex. Based on race, black males had worse 5-yrOS and 5yr-DSS, followed by white males, black females, and white females (p= 0.0001)(Table1b). Conclusions: Even though MBC presents with advanced disease at diagnosis, our analysis shows there is no difference in DSS when analyzed stage-by-stage. White females had better prognosis compared to others, and black males had worse prognosis. Prospective studies needed to be done to evaluate the prognosis of male breast cancer. [Table: see text] [Table: see text]

Survival trends in chronic lymphocytic leukemia in the era of oral targeted therapies in the United States: SEER database analyses (1985 to 2017).

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. 7524-7524
Author(s):  
Neda Alrawashdh ◽  
Ali McBride ◽  
Daniel O. Persky ◽  
Joann Sweasy ◽  
Brian Erstad ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Survival Rates ◽  
Relative Survival ◽  
Lymphocytic Leukemia ◽  
Disease Stage ◽  
Seer Database ◽  
Cure Model ◽  
Gender And Age ◽  
Long Term Survivors

7524 Background: The survival of chronic lymphocytic leukemia (CLL) patients has progressively improved after the approval of new targeted therapy for first-line treatment and relapsed disease. We performed a corresponding analysis from the U.S. population-based SEER database (1973–2017) to explore the trend of survival and the effect of advanced CLL treatment on overall survival in CLL patients. Methods: Data were extracted from SEER*Stat for all patients 15 years or older with a primary diagnosis of CLL with or without subsequent cancers. A period analysis was performed to estimate the 5- and 10-year relative survival rates for patients diagnosed (dx) during different calendar periods from 1985 to 2017, based on gender and age at time of diagnosis (15–44, 45–54, 55–64, 65–74, 75–84, 85 years or older). A mixture cure model was used to examine the proportion of long-term survivors per gender and age category among CLL patients diagnosed between 1985 and 2015. Cox proportional hazard modeling was used to calculate the hazard ratios (HRs) of death adjusted for gender and age at diagnosis for two cohorts: (a) diagnosed in 2000–2003 and followed to 2012; (b) 2004–2007 and followed to 2015. Results: For males, the 5-year age-adjusted relative survival rate improved progressively from 72.0% (dx 1985-1989) to 88.2% (dx 2010-2014); for females, from 76.8% (dx 1985-1989) to 90.8% (dx 2010-2014). The corresponding 10-year age-adjusted relative survival rates were 47.3% (dx 1985-1989) and 72.5% (dx 2005-2009) for males; and 58.2% (dx 1985-1989) and 78.7% (dx 2005-2009) for females. The table below shows the proportions of long-term survivors for the 1985–2017 cohort as estimated in the mixed cure model. The HRs (95%CI) of death for cohort (b) in comparison to cohort (a) were 0.58 (0.43–0.78), 0.58 (0.48–0.70), 0.57 (0.49–0.67), 0.68 (0.54–0.85); and 0.83 (0.68–1.02) for age categories of 45–54, 55–64, 65–74, 75–84, and 85 years or old. Conclusions: Survival is significantly improved by calendar period among patients diagnosed after 2004 and treated in the era of advanced therapies. Females and younger patients had a higher probability of long term survival. Future studies should consider such covariates as treatment type, disease stage and genetics.[Table: see text]

Survival of red-capped robins (Petroica goodenovii) in woodland remnants of central western New South Wales, Australia

2001 ◽  
Vol 28 (6) ◽  
pp. 565 ◽  
Author(s):  
Richard E. Major ◽  
Greg Gowing
Keyword(s):  
Survival Rates ◽  
Relative Survival ◽  
Adult Mortality ◽  
Annual Survival ◽  
Survival Probabilities ◽  
South Wales ◽  
Winter Half ◽  
Linear Habitat ◽  
Significant Difference ◽  
Summer Half

To determine relative survival rates of small birds occupying small, linear strips of woodland compared with large patches of woodland, marked populations of red-capped robins were monitored over a two-year period. In total, 196 male robins were banded with unique colour combinations in 10 woodland remnants and censused by song playback at half-yearly intervals. The Cormack–Jolly–Seber method was used to calculate half-yearly survival probabilities for birds in the two habitat configurations and the strongest model included separate survival parameters for summer (36.2% 5.1) and autumn (88.9% 13.5) half-years, but a constant recapture probability (50.5% 7.2). The inclusion of separate parameters for the large and linear habitat configurations reduced the strength of the model, indicating that there was no significant difference between the survival rates of birds occupying small, linear strips of woodland and birds occupying large patches of woodland. The mean annual survival, determined by multiplying the half-yearly survival probabilities, was 32%, which is low, compared with the annual survival of other Petroica robins. Although no banded birds were located away from the banding site, we suspect that much of the ‘mortality’ represented emigration during the summer half-year. Under this scenario a better estimate of annual survival (79%) might be achieved by extrapolation of survival over the winter half-year. This study provides no data to support the contention that adult mortality is higher in small, linear strips of habitat, although further data on the fate of birds that disappear from remnants is required before this is conclusive. In addition, to detect a 20% difference in survival using similar methods to the present study, with their accompanying sources of variation, at least 10 times the number of birds would need to be monitored. This might most effectively be done as a co-operative banding project.

scholarly journals Analysis of prognostic factors for melanoma patients

2017 ◽  
Vol 24 (1) ◽  
pp. 25-34 ◽  
Author(s):  
Andrė Lideikaitė ◽  
Julija Mozūraitienė ◽  
Simona Letautienė
Keyword(s):  
Prognostic Factors ◽  
Survival Rates ◽  
Age Groups ◽  
Anatomical Site ◽  
Skin Melanoma ◽  
Histological Subtypes ◽  
Nodular Melanoma ◽  
Histological Types ◽  
Survival Difference ◽  
Significant Difference

Introduction. Melanoma is the most dangerous form of skin cancer. Morbidity from melanoma is increasing every year. Previous studies have revealed that there are some demographic and clinical factors having effect on melanoma survival prognosis. Aim of the study. Purpose of our study was to assess melanoma survival depending on prognostic factors, such as age, sex, stage, depth, histology and anatomical site. Materials and methods. We investigated melanoma-specific survival up to 10 years in 85 primary cases of melanoma from diagnosis at the National Cancer Institute in 2006. Analysis was performed for one-, five-, and ten-year survival. The data were processed with Microsoft Excel, data analysis was conducted using SPSS® software. Results. Melanomas diagnosed at stage IV or thicker than 4.00 mm had lower survival (five-year survival: 12.5% and 26.66%, respectively). A significant survival difference was observed among the different stages (p = 0.003) and different depths (p = 0.049) of melanoma. Ten-year survival was 32% for men and 61% for women, but melanoma-specific survival dependent on sex did not have a statistically significant difference (p = 0.121). In persons diagnosed at the age of 65 or older, ten-year survival was lower than in those of 40–64 years of age and in the  age group of 15–39 years (44.44% and 26.66%, respectively), but melanoma-specific survival in different age groups did not have a statistically significant difference (p = 0.455). Back/breast skin melanoma had lower ten-year survival (37.03%) than other anatomic sites. Nodular melanoma had the poorest five-year and ten-year melanoma-specific survival among histological subtypes (51.67% and 38.75%). The differences between melanoma localizations (p = 0.457) and histological types (p = 0.364) were not statistically significant. Conclusions. Lower melanoma-specific survival rates were observed among patients diagnosed at a late stage, older age, and when melanomas were thicker than 4.00 mm. Female and younger patients had better melanoma-specific survival than men and older people, and these differences were statistically significant. Melanoma diagnosed at an early stage and of a  small depth had higher survival rates. Back/breast skin melanoma had poorer prognosis than other anatomic sites. Nodular melanoma had the  lowest melanoma-specific survival, while superficial spreading or lentigo maligna had the best prognosis among histological subtypes. However, differences in melanoma survival in different sex and age groups, localizations and histological types were not statistically significant.

Hodgkin Lymphoma Outcomes: Can We Expect Ethnic Parity in a Hispanic Prevalent Population?

Blood ◽  
2019 ◽  
Vol 134 (Supplement_1) ◽  
pp. 4056-4056
Author(s):  
Michelle Janania Martinez ◽  
Prathibha Surapaneni ◽  
Juan F Garza ◽  
Tyler W Snedden ◽  
Snegha Ananth ◽  
...  
Keyword(s):  
Hodgkin Lymphoma ◽  
Conflicts Of Interest ◽  
Relative Survival ◽  
Complete Response ◽  
Statistical Testing ◽  
P Value ◽  
Hispanic Population ◽  
Significant Difference ◽  
The Mean

BACKGROUND It is estimated that 8110 persons will be diagnosed with Hodgkin Lymphoma (HL) in the US during 2019, but the advent of new treatment options has increased the cure rate to at least 80%. It has been reported that the rates of HL are lower in the adolescent and young adult (AYA) Hispanic population but significantly higher in the Hispanic population older than 65. The relative survival estimates are stated to be similar between AYA Hispanics (HI) and non-Hispanics (NH) but for ages 65-84, HI have a significantly higher mortality rate. Pediatric studies have suggested that ethnicity plays a role in outcomes in patients with HL but there is limited data in the adult population. There is an unmet need in the field, where dossiers on underrepresented ethnic minorities need to be carefully considered and compared to existing data. Therefore, our study aims to compare survival outcomes in Hispanics vs Non-Hispanics with HL, who were treated at the only NCI designated cancer center of South Texas. To our knowledge this is the largest cohort of HL patients from a single academic institution that serves primarily Hispanics. METHODS We located and retrospectively analyzed a total of 616 patients with diagnosis of Lymphoma (HL and NHL) by International Classification of Diseases (ICD) codes and identified 116 cases of HL; all the patients received care at UT Health San Antonio, between 2008-2018. Key variables for each patient included age, gender, race/ethnicity, comorbidities, insurance status, stage, BM and extranodal involvement, treatment received, outcome at 3 and 5 years and vitality status in 2018. Continuously distributed outcomes were summarized with the mean and standard deviation and categorical outcomes were summarized with frequencies and percentages. The significance of variation in the mean with disease category was assessed with one way ANOVA and the significance of associations between categorical outcomes was assessed with Pearson's Chi Square or Fisher's Exact test as appropriate. Multivariate logistic regression was used to model binary outcomes in terms of covariates and indicators of disease. All statistical testing was two-sided with a significance level of 5%. R1 was used throughout. The study was approved by the local Institutional Review Board. The findings will be available to patients, funders and medical community through traditional publishing and social media. RESULTS We identified 116 patients with HL, of which 73 were HI (63%), 43 NH (36%) and 1 not specified (1%). In regard to race, 92% identified as Caucasian, 4% as African American, 3% other and 1% Asian. The median age at diagnosis was 37.4, (SD 15.13). There were 49 females (42%) and 67 males (58%). The most common funding source was commercial insurance N=54 (47%), followed by a hospital payment plan N=30 (26%), Medicare N=16 (14%), unfunded N=13 (11%) and Medicaid N=3 (2%). Most prevalent co-morbidities were HTN N=28 (24%) and diabetes mellitus N= 23(20%); 50% of patients had no co-morbidities (N=63).At diagnosis ECOG of 0-1 was seen in 108 patients (93%); 8 were Stage I (7%), 39 stage II (33%), 32 stage III (28%), and 37 stage IV (32%). EBV was positive in 26 patients (22%). There were 15 patients that were HIV positive (13%), 54% with CD4 count <200, and 12 (75%) on antiretroviral therapy at diagnosis. Median PFS was 853.85 days (SD 912.92). We excluded patients who were lost to follow up or had not reached 3/5 years. At 3 year follow up there was: complete response in 37 HI (74%) vs 22 NH (92%); disease progression in 8 (16%) vs 0 (0%); death in 5 (10%) vs 2 (8%), respectively (p-value= 0.094). At 5 year follow up there was: complete response in 30 HI (77%) vs 17 NH (90%); progressive disease in 2 (5%) vs 0 (0); death 7 (18%) vs 2 (11%), respectively (p-value = 0.619). At the end of 2018, 41 HI (84%) were alive compared to 22 NH (88%) [p-value 0.74]. CONCLUSION Within the limitations of sample size, our study demonstrates that in the prevalently Hispanic population of our institution, HI patients with HL have no statistically significant difference in outcome when compared to NH patients. Disclosures No relevant conflicts of interest to declare.

Disparities in receipt of radiotherapy and survival by age, sex, and race among patients with nonmetastatic squamous cell carcinoma of the anus.

2015 ◽  
Vol 33 (3_suppl) ◽  
pp. 721-721
Author(s):  
Doug Baughman ◽  
Krishna Bilas Ghimire ◽  
Binay Kumar Shah
Keyword(s):  
Proportional Hazards ◽  
Proportional Hazards Model ◽  
Survival Rates ◽  
Relative Survival ◽  
Population Based ◽  
Cox Proportional Hazards ◽  
Cox Proportional Hazards Model ◽  
P Value ◽  
Hazards Model ◽  
To Receive

721 Background: Combination chemoradiotherapy is the standard of care for treatment of non-metastatic squamous cell carcinoma of the anus (SCCA). This population-based study evaluated disparities in receipt of radiotherapy (RT) and its effect on survival in patients with localized and regional SCCA in the United States. Methods: The Surveillance, Epidemiology, and End Results (SEER) 18 database was used to identify patients with localized and regional SCCA diagnosed between 1998 and 2008. We used univariate and multivariate logistic regression to model the relationships between receipt of RT and age, sex, marital status, stage, and race. Relative survival rates were calculated and compared using two sample z-tests. A Cox proportional hazards model was used to find adjusted hazard ratios (HR). Results: A total of 3,971 patients with localized or regional SCCA as the only primary malignancy were included in the study, of which 3,278 (82.6%) received RT. After adjusting for covariates, those 65 years and older (adjusted OR 0.82, p=0.029) were less likely to receive RT. Females were more likely to receive RT compared to males (adjusted OR 1.54, p<0.001). We found no difference in receipt of RT by race. Comparisons of 1- and 5-year relative survival rates showed lower survival for blacks (p-value <0.01 at 1-year and <0.0001 at 5-years), those 65 years and older, and males. A 1-year survival disparity was found for those not receiving RT (p-value <0.0001 at 1-year), but no difference was observed at 5-years. A Cox proportional hazards model adjusting for all covariates showed greater hazard for blacks (adjusted HR 1.36, p=0.001), those not receiving RT (adjusted HR 1.23, p=0.03), patients 65 years or older, and males. Conclusions: This population based study identified older patients as less likely to receive RT and females as more likely to receive RT. Survival analysis identified blacks, males, older patients, and those not receiving RT as having lower rates of survival.

Survival Trends among Patients with Advanced Renal Cell Carcinoma in the United States

2014 ◽  
Vol 94 (2) ◽  
pp. 133-136 ◽  
Author(s):  
Binay Kumar Shah ◽  
Krishna Bilas Ghimire
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Survival Rates ◽  
Relative Survival ◽  
The United States ◽  
Population Based ◽  
Advanced Renal Cell Carcinoma ◽  
Targeted Agents ◽  
Significant Difference

Introduction: Since the approval of sorafenib in December 2005, several targeted therapeutic agents have been approved by the FDA for the treatment of advanced renal cell carcinoma (RCC). This study was conducted to find out whether the improvements in survival of advanced RCC patients with targeted agents have translated into a survival benefit in a population-based cohort. Methods: We analyzed the SEER 18 (Surveillance, Epidemiology and End Results) registry database to calculate the relative survival rates for advanced RCC patients during 2001-2009, 2001-2005, 2006-2007 and 2008-2009. We also evaluated the survival rates by age (<65 and ≥65 years) and sex. Results: The total number of advanced RCC patients during 2001-2009, 2001-2005, 2006-2007 and 2008-2009 were 7,047, 4,059, 1,548 and 1,440, respectively. During 2001-2009, the 1- and 3-year relative survival rates were 26.7 ± 0.6 and 10.0 ± 0.4%, respectively. There was no significant difference in 1-year relative survival rates for patients diagnosed during 2006-2007 and 2008-2009 compared to those diagnosed during 2001-2005. Similarly, the 3-year survival rates for patients diagnosed during 2006-2007 were similar to those diagnosed during 2001-2005. Conclusions: This population-based study showed that there was no significant improvement in relative survival rates among advanced RCC patients in the era of targeted agents.

Sign in / Sign up

Export Citation Format

Share Document